Premier Alternatives

Zenshine Pharmaceuticals (Nanjing) Group

Nanjing, China · Founded 2018 · In IPO Registration

Developer and provider of innovative antiviral and oncology therapies designed for unmet clinical needs in viral infections, cancer, and inflammatory diseases. Zenshine Pharmaceuticals (Nanjing) Group is based in Nanjing, China and was founded in 2018. Its last reported valuation was $354 million in Jan 2026. It has raised $127 million.

Last reported valuation
$354.4M
Oct 2026
Priced at
—
Total raised
$126.6M
Last round
—

Zenshine Pharmaceuticals (Nanjing) Group key facts

as of Oct 2026
  • Developer and provider of innovative antiviral and oncology therapies designed for unmet clinical needs in viral infections, cancer, and inflammatory diseases.
  • Zenshine Pharmaceuticals (Nanjing) Group is valued at approximately $354.4M as of Oct 2026 (last reported valuation).
  • It has raised $126.6M; the latest was IPO in Jan 2026.
  • Notable investors include China Capital Management, CMG SDIC Fund, Tailong VC, Proxima Ventures (China), Changxing Fund — 21 tracked in total.
  • Status: In IPO Registration.
Last reported valuation
LOW confidence
$354.4M

Zenshine Pharmaceuticals (Nanjing) Group's last reported valuation, Jan 2026. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Zenshine Pharmaceuticals (Nanjing) Group with a free account
  • ·The complete investor list: 21 names
  • ·Watch Zenshine Pharmaceuticals (Nanjing) Group: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Zenshine Pharmaceuticals (Nanjing) Group funding rounds

No rounds on record

No funding rounds for Zenshine Pharmaceuticals (Nanjing) Group are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Zenshine Pharmaceuticals (Nanjing) Group valuation

Zenshine Pharmaceuticals (Nanjing) Group's last reported valuation was $354 million in Jan 2026. No priced round, secondary trade or fund mark has surfaced since.

Zenshine Pharmaceuticals (Nanjing) Group investors

21 investors are on record for Zenshine Pharmaceuticals (Nanjing) Group, including China Capital Management, CMG SDIC Fund, Tailong VC and Proxima Ventures (China).

About Zenshine Pharmaceuticals (Nanjing) Group

Developer and provider of innovative antiviral and oncology therapies designed for unmet clinical needs in viral infections, cancer, and inflammatory diseases. The company provides a portfolio including the next-generation influenza polymerase acidic protein inhibitor baloxavir marboxil and ENPP1 inhibitors for cancer treatment, enabling healthcare providers with more effective and accessible therapeutic options.

Sector
Healthcare
HQ
Nanjing, China
Founded
2018
Employees
77
Ownership
In IPO Registration

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.